Potentiation of the antitumor effects of imidazoquinoline immune response modifiers by cyclophosphamide

Cancer Biology and Therapy

Volumn 10, Issue 2, 2010, Pages 155-165

  Dumitru, Calin D ^a   Antonysamy, Mary A ^b   Tomai, Mark A ^c   Lipson, Kenneth E ^d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Biothera   (United States)

^c 3M COMPANY   (United States)

^d FIBROGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

852A; CYCLOPHOSPHAMIDE; IMIDAZOQUINOLINE DERIVATIVE; N [2 (4 AMINO 2 ETHOXYMETHYL 1H IMIDAZO[4,5 C]QUINOLIN 1 YL) 1,1 DIMETHYLETHYL]METHANESULFONAMIDE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; N (4 (4 AMINO 2 ETHYL 1H IMIDAZO(4,5C)QUINOLIN 1 YL)BUTYL)METHANESULFONAMIDE; N-(4-(4-AMINO-2-ETHYL-1H-IMIDAZO(4,5C)QUINOLIN-1-YL)BUTYL)METHANESULFONAMIDE; QUINOLINE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MELANOMA; MOUSE; NONHUMAN; ADJUVANT CHEMOTHERAPY; ANIMAL; C57BL MOUSE; CELL STRAIN HEK293; COLON TUMOR; DBA MOUSE; DRUG EFFECT; EXPERIMENTAL MELANOMA; IMMUNOLOGY; IMMUNOMODULATION; LUNG TUMOR; METABOLISM; NONPARAMETRIC TEST; PATHOLOGY; TUMOR CELL CULTURE; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; CYCLOPHOSPHAMIDE; HEK293 CELLS; HUMANS; IMMUNOMODULATION; INTERFERON TYPE I; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MODELS, ANIMAL; NF-KAPPA B; QUINOLINES; STATISTICS, NONPARAMETRIC; SULFONAMIDES; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 77955433721     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.2.12163     Document Type: Article

References (44)

1. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009; 388:621-5.
2. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13:552-9.
3. Sidky YA, Borden EC, Weeks CE, Reiter MJ, Hatcher JF, Bryan GT. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res 1992; 52:3528-33.
4. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1999; 21:1-14.
5. Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hammerling GJ. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001; 167:5247-53.
6. Krepler C, Wacheck V, Strommer S, Hartmann G, Polterauer P, Wolff K, et al. CpG oligonucleotides elicit antitumor responses in a human melanoma NOD/SCID xenotransplantation model. J Invest Dermatol 2004; 122:387-91.
7. Gauvreau GM, Hessel EM, Boulet LP, Coffman RL, O'Byrne PM. Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am J Respir Crit Care Med 2006; 174:15-20.
8. Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005; 105:489-95.
9. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007; 117:1184-94.
10. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355:1445-55.
11. Krieg AM. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 2007; 4:289-94.
12. Slade HB, Owens ML, Tomai MA, Miller RL. Imiquimod 5% cream (Aldara). Expert Opin Investig Drugs 1998; 7:437-49.
13. Palamara F, Meindl S, Holcmann M, Luhrs P, Stingl G, Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 2004; 173:3051-61.
14. Keller CD. Imiquimod to treat basal cell and squamous cell carcinomas. Am Fam Physician 2005; 72:41. (Pubitemid 40962019)
15. Peris K, Campione E, Micantonio T, Marulli GC, Fargnoli MC, Chimenti S. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg 2005; 31:318-23.
16. Bong AB, Bonnekoh B, Franke I, Schon MP, Ulrich J, Gollnick H. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology (Basel, Switzerland) 2002; 205:135-8.
17. Fisher GH, Lang PG. Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Archives of dermatology 2003; 139:945-7.
18. Mandekou-Lefaki I, Delli F, Koussidou-Eremondi T, Mourellou-Tsatsou O, Dionyssopoulos A. Imiquimod 5% cream: a new treatment for Bowen's disease. Int J Tissue React 2005; 27:31-8.
19. Martin-Garcia RF. Imiquimod: an effective alternative for the treatment of invasive cutaneous squamous cell carcinoma. Dermatol Surg 2005; 31:371-4.
20. Wolf IH, Cerroni L, Kodama K, Kerl H. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Archives of dermatology 2005; 141:510-4.
21. Dudek AZ, Yunis C, Kumar S, Harrison LI, Hawkinson RW, JS M. Immune response activation by a Toll-like receptor 7 agonist: Results of a phase 1 study. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings 2005; 23:2515.
22. + cells mediate the anti-tumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. Cancer Immunol Immunother 2009; 58:575-87.
23. Hammerbeck DM, Burleson GR, Schuller CJ, Vasilakos JP, Tomai M, Egging E, et al. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antiviral Res 2007; 73:1-11. (Pubitemid 46080481)
24. Riker AI, Radfar S, Liu S, Wang Y, Khong HT. Immunotherapy of melanoma: a critical review of current concepts and future strategies. Expert Opin Biol Ther 2007; 7:345-58.
25. Makinodan T, Santos GW, Quinn RP. Immunosuppressive drugs. Pharmacological reviews 1970; 22:189-247.
26. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004; 6:88-95.
27. Balsari A, Tortoreto M, Besusso D, Petrangolini G, Sfondrini L, Maggi R, et al. Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur J Cancer 2004; 40:1275-81.
28. Vicari AP, Luu R, Zhang N, Patel S, Makinen SR, Hanson DC, et al. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 2009; 58:615-28.
29. Wang XS, Sheng Z, Ruan YB, Guang Y, Yang ML. CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma. World J Gastroenterol 2005; 11:1220-4.
30. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003; 9:3105-14.
31. Murad YM, Clay TM, Lyerly HK, Morse MA. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol Ther 2007; 7:1257-66.
32. Medscape. Monograph-Cyclophosphamide. Medscape 2010.
33. Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002; 218:74-86.
34. Koziol JA, Maxwell DA, Fukushima M, Colmerauer ME, Pilch YH. A distribution-free test for tumorgrowth curve analyses with application to an animal tumor immunotherapy experiment. Biometrics 1981; 37:383-90.
35. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002; 3:499. (Pubitemid 34669818)
36. Corbett TH, Polin L, Roberts BL, Lawson AJ, Leopold WR, III, White K, et al. Transplantable syngeneic rodent tumors: solid tumors of mice. In: Teicher BA, ed. Tumor models in cancer research. Totowa, NJ: Humana Press 2002; 41-71.
37. Pharmacology of Cancer Chemotherapy. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia: Lippincot, Williams and Wilkins 2005.
38. Lake RA, Robinson BW. Immunotherapy and chemotherapy - a practical partnership. Nature reviews 2005; 5:397-405.
39. Gorden KK, Qiu XX, Binsfeld CC, Vasilakos JP, Alkan SS. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J Immunol 2006; 177:6584-7.
40. Schon MP, Schon M. The small-molecule immune response modifier imiquimod - its mode of action and clinical use in the treatment of skin cancer. Expert opinion on therapeutic targets 2006; 10:69-76. (Pubitemid 43263267)
41. Naylor M. Imiquimod and superficial skin cancers. J Drugs Dermatol 2005; 4:598-606.
42. Naylor MF, Chen WR, Teague TK, Perry LA, Nordquist RE. In situ photoimmunotherapy: a tumour-directed treatment for melanoma. The British journal of dermatology 2006; 155:1287-92.
43. Redondo P, del Olmo J, Lopez-Diaz de Cerio A, Inoges S, Marquina M, Melero I, et al. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol 2007; 127:1673-80.
44. Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F, et al. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 2000; 95:2024-30.